• Customer Care
  • (888) 123-4567

POSTDOCTORAL SCIENTIST

Rise Therapeutics is recruiting a postdoctoral scientist with a background in molecular biology, immunology, and/or microbial genetic research to work in our Rockville, Maryland laboratory. This candidate should have a strong interest in developing innovative new immunological therapies. Our Postdoctoral Scientist Program offers a unique opportunity for entrepreneurial minded scientists to develop the skills and experience necessary for a successful career in the biotechnology industry. The Postdoctoral Scientist will lead research programs and product development strategies to generate pre-clinical validation datasets to support drug development programs.

Required Qualifications

  • Advanced degree (PhD and/or MD) in the life sciences
  • Background in molecular biology, immunology, and/or microbial genetic research
  • Strong verbal and written communication skills
  • Ability to contribute in a fast-paced, highly dynamic environment
  • Strong sense of responsibility for deadlines and data accuracy
  • Ability to deliver results in a highly independent environment
  • Rigor and attention to detail in all aspects of science
  • Ability to exercise discretion when handling confidential or sensitive information
  • Comfort with collaboration in a team-based environment 

Benefits

  • Develop new therapies to treat autoimmunity, infection, and cancer
  • Gain experience working in biotech
  • Mentorship from seasoned entrepreneurs and business executives
  • Ability to patent discoveries and better understand intellectual property management
  • Opportunities to publish and attend/present at scientific meetings
  • Expand relationships/connections with leading academic innovators and global biotechnology/pharmaceutical partners

 

About Rise Therapeutics

Rise Therapeutics is an emerging, privately held biotech company located in Rockville, Maryland, which develops novel synthetic biology-based medicines. As a product focused company, we leverage our proprietary drug delivery platform and GMP manufacturing infrastructure to create targeted immunologically-directed Live Biotherapeutic Products (LBPs). Rise harnesses novel discoveries in microbiome biology as it relates to regulation of immune function to identify new immune regulatory pathways and develop unique, first-in-class immune modulatory drugs for the treatment of autoimmunity, inflammation, infection, and cancer. For more information, please visit our website at www.risetherapeutics.com

 

Please email your CV or resume to: This email address is being protected from spambots. You need JavaScript enabled to view it.

Title document as "last name first inital-title of position-resume.pdf" e.g. "DoeJ-PostDoc-resume.pdf"

Our News

Rockville, MD. Rise Therapeutics announced today that they have successfully initiated operations of their GMP manufacturing facility based in Rockville, MD.  Funding to help set up this GMP manufacturing operation came from the National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program Grant, which assists small businesses with technical assistance and late-stage development projects that are not typically supported by SBIR and STTR Phase II and Phase IIB grants. Launching of operations for this facility was also supported by the financial contributions of the Montgomery County Economic Development Corporation.  

Rockville, MD. Rise Therapeutics, a company that develops innovative immune therapies, announced today that it initiated a new program to develop a novel, immunologically enhanced microbiome drug for the treatment of cancer. This product candidate, R-5780, engages key immune pathways regulated by the microbiome to enhance the effectiveness of immune checkpoint inhibitor (ICI) therapy to treat cancer. Coinciding with the timing of this release, Rise has secured funding to support key product development initiatives for the program.

Rockville, MD. Rise Therapeutics, a biotechnology company developing first-in-class targeted immunological-based biologics using a unique and proprietary oral delivery platform, announced today the publication of the co-authored article, “Lactococcus lactis Delivery of Surface Layer Protein A Protects Mice from Colitis by Re-Setting Host Immune Repertoire” in the journal Biomedicines.